Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • North Carolina
  • Raleigh


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Effect of Dry Roasted Peanuts and Boiled Peanuts on Glycemic Control
    NCT04171648
    Conditions:   Diabetes Mellitus;   Glycemic Control
    Interventions:   Other: Roasted Peanut Treatment;   Other: Boiled Peanut Treatment
    Sponsor:   North Carolina State University
    Recruiting
  • Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
    NCT03513549
    Condition:   Agitation,Psychomotor
    Intervention:   Drug: Loxapine 10 MG
    Sponsors:   Galen Limited;   Pharmaceutical Research Associates
    Recruiting
  • Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
    NCT04188197
    Conditions:   Smoking Cessation;   Harm Reduction;   E-Cig Use;   Cigarette Smoking;   Tobacco Dependence;   Tobacco Use Cessation
    Intervention:   Other: JUUL
    Sponsors:   Rose Research Center, LLC;   Foundation for a Smoke-Free World
    Recruiting
  • Optimizing Overactive Bladder Treatment
    NCT03904407
    Condition:   Overactive Bladder
    Interventions:   Other: Lactobacillus Probiotic Capsule;   Other: Matching Lactobacillus Probiotic Placebo Capsule
    Sponsors:   University of North Carolina, Chapel Hill;   Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
    Recruiting
  • Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
    NCT03867045
    Condition:   Metastatic Renal Cell Carcinoma Treated With Cabozantinib
    Intervention:   Device: Usability of an electronic symptom management application
    Sponsors:   Duke University;   Exelixis
    Recruiting
  • Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
    NCT02870218
    Conditions:   Nicotine Addiction;   Cigarette Smoking
    Interventions:   Drug: Smoking research cigarettes with e-cigarette;   Drug: Nicotine discrimination thresholds
    Sponsors:   Rose Research Center, LLC;   National Institutes of Health (NIH);   Food and Drug Administration (FDA);   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Longitudinal Effects of a Sexual Health Intervention: HEART
    NCT04156516
    Conditions:   STD;   Adolescent Behavior
    Interventions:   Behavioral: HEART;   Behavioral: HealthyMinds
    Sponsor:   North Carolina State University
    Recruiting
  • Placebo Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients
    NCT04040816
    Conditions:   Gout;   Hyperuricemia
    Intervention:   Drug: SAP-001
    Sponsor:   Shanton Pharma Co., Ltd.
    Recruiting
  • Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
    NCT03944707
    Condition:   Asthma
    Intervention:   Drug: LOU064 or placebo treatment
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
    NCT03077243
    Conditions:   Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
    Interventions:   Radiation: Intensity Modulated Radiotherapy (IMRT) - deintensified;   Radiation: Intensity Modulated Radiotherapy (IMRT) - standard;   Drug: Cisplatin (or alternative) - deintensified;   Drug: Cisplatin (or alternative) - standard;   Procedure: Assessment for surgical evaluation
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting
  • Environmental Polymorphisms Registry
    NCT00341237
    Conditions:   Diabetes;   Heart Disease;   Asthma
    Intervention:  
    Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
    Recruiting
  • Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
    NCT02852239
    Condition:   Renal Impairment
    Intervention:   Drug: dabrafenib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
    NCT03281954
    Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Placebo;   Drug: Atezolizumab
    Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
    Recruiting
  • Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
    NCT02993406
    Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
    Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
    Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
    NCT02364557
    Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
    Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
    NCT04003389
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
    NCT04003155
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
    NCT03922711
    Condition:   Parkinson Disease
    Interventions:   Drug: Pridopidine;   Drug: Placebo
    Sponsor:   Prilenia
    Recruiting
  • To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
    NCT03777059
    Condition:   Episodic Migraine
    Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
    Sponsor:   Allergan
    Recruiting
  • A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
    NCT03561090
    Condition:   Gastroesophageal Reflux Disease (GERD)
    Interventions:   Drug: IW-3718;   Drug: placebo
    Sponsor:   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
    NCT03551496
    Condition:   Critical Limb Ischemia
    Interventions:   Combination Product: Drug Eluting Stent - Below the Knee;   Device: Standard PTA Control Arm
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Hemodynamic-GUIDEd Management of Heart Failure
    NCT03387813
    Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure,Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
    Intervention:   Device: CardioMEMS™ HF System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
    NCT03035474
    Condition:   Heart Failure
    Interventions:   Other: Digital Engagement;   Other: Direct Engagement
    Sponsors:   Duke University;   Duke Clinical Research Institute
    Recruiting
  • Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
    NCT02923193
    Condition:   Peripheral Arterial Disease
    Interventions:   Device: Shockwave Lithoplasty® Peripheral Lithoplasty System;   Drug: Medtronic IN.PACT (DCB)
    Sponsor:   Shockwave Medical, Inc.
    Recruiting
  • Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
    NCT02877134
    Condition:   Crohn Disease
    Interventions:   Drug: JNJ-64304500;   Drug: Placebo;   Drug: Ustekinumab
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
    NCT03290508
    Condition:   Prostate Cancer
    Intervention:   Diagnostic Test: Prolaris Testing
    Sponsor:   Myriad Genetic Laboratories, Inc.
    Recruiting
  • Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis
    NCT03042104
    Conditions:   Aortic Stenosis;   Heart Diseases
    Intervention:   Device: Edwards SAPIEN 3 THV
    Sponsor:   Edwards Lifesciences
    Recruiting
  • Registry of Older Patients With Cancer
    NCT01137825
    Conditions:   Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:  
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Transvenous Lead Removal Post-Market Clinical Study
    NCT03688412
    Condition:   Cardiac Electrophysiology
    Intervention:   Device: Cook lead extraction devices
    Sponsor:   Cook Research Incorporated
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Comparative Effectiveness Study Telerehab Versus Conventional
    NCT03468868
    Condition:   Multiple Sclerosis
    Intervention:   Behavioral: Exercise program for people with MS
    Sponsors:   Shepherd Center, Atlanta GA;   University of Alabama at Birmingham;   University of North Carolina, Chapel Hill;   University of Georgia;   The Cleveland Clinic;   University of Colorado, Denver;   Marquette University;   Accelerated Cure Project for Multiple Sclerosis;   Patient-Centered Outcomes Research Institute
    Recruiting
  • A Registry for Hereditary Cancer Risk Assessment and Genetic Testing
    NCT04015102
    Condition:   Prostate Cancer
    Intervention:  
    Sponsors:   Myriad Genetic Laboratories, Inc.;   Carolina Urologic Research Center
    Recruiting
  • AltaValve Early Feasibility Study Protocol
    NCT03997305
    Conditions:   Mitral Regurgitation;   Mitral Insufficiency;   Mitral Valve Incompetence;   Mitral Valve Regurgitation;   Mitral Incompetence
    Intervention:   Device: AltaValve
    Sponsor:   4C Medical Technologies, Inc.
    Recruiting
  • A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
    NCT04172831
    Condition:   Fibromyalgia
    Interventions:   Drug: TNX-102 SL;   Drug: Placebo SL Tablet
    Sponsor:   Tonix Pharmaceuticals, Inc.
    Recruiting
  • Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
    NCT04142242
    Condition:   Meningococcal Infection (Healthy Volunteers)
    Interventions:   Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Other: Blood sample
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
    NCT04028492
    Conditions:   Idiopathic Gastroparesis;   Diabetic Gastroparesis;   Gastroparesis
    Interventions:   Drug: Tradipitant;   Drug: Placebo
    Sponsor:   Vanda Pharmaceuticals
    Recruiting
  • Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
    NCT03980730
    Condition:   Alzheimer Disease
    Interventions:   Drug: Azeliragon;   Drug: Placebo
    Sponsor:   vTv Therapeutics
    Recruiting
  • A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia
    NCT03965091
    Condition:   Fibromyalgia
    Interventions:   Drug: Fremanezumab - Dose A;   Drug: Fremanezumab - Dose B;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
    NCT02720744
    Conditions:   Excessive Daytime Sleepiness;   Cataplexy;   Narcolepsy
    Interventions:   Drug: Sodium Oxybate;   Drug: Placebo
    Sponsor:   Avadel
    Recruiting
  • A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)
    NCT03933202
    Condition:   Multiple Sclerosis
    Intervention:   Drug: Cladribine Tablets
    Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
    NCT03931785
    Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
    Interventions:   Drug: MD-7246;   Drug: Placebo
    Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
    Recruiting
  • Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
    NCT03918629
    Condition:   Clostridium Difficile Associated Disease
    Interventions:   Biological: Clostridium difficile;   Biological: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
    NCT03902080
    Condition:   Overactive Bladder
    Interventions:   Drug: Vibegron;   Drug: Placebo
    Sponsor:   Urovant Sciences GmbH
    Recruiting
  • A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
    NCT03901482
    Conditions:   Migraine;   Migraine With Aura;   Migraine Without Aura
    Interventions:   Drug: Dihydroergotamine;   Drug: Placebos
    Sponsor:   Satsuma Pharmaceuticals, Inc.
    Recruiting
  • A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
    NCT03899259
    Condition:   Alopecia Areata
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   Incyte Corporation
    Recruiting
  • An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
    NCT03896295
    Condition:   Generalized Myasthenia Gravis
    Intervention:   Drug: M281
    Sponsor:   Momenta Pharmaceuticals, Inc.
    Recruiting
  • Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
    NCT03855137
    Condition:   Chronic Migraine
    Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
    NCT03851445
    Condition:   Previously Treated Non-Small Cell Lung Cancer
    Intervention:   Drug: Screening Platform
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
    NCT03850483
    Condition:   Psoriasis
    Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
    Sponsor:   Pfizer
    Recruiting
  • XIENCE 28 USA Study
    NCT03815175
    Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
    Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
    NCT03803202
    Conditions:   Healthy Volunteers;   Pneumococcal Disease
    Interventions:   Biological: ASP3772;   Biological: PCV13;   Biological: PPSV23
    Sponsors:   Astellas Pharma Global Development, Inc.;   Affinivax
    Recruiting
  • Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
    NCT03781791
    Conditions:   Constipation;   Parkinson Disease
    Interventions:   Drug: Active Investigational Treatment ENT-01;   Drug: Placebo Treatment
    Sponsor:   Enterin Inc.
    Recruiting
  • A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
    NCT03781167
    Condition:   Parkinson's Disease (PD)
    Intervention:   Drug: ABBV-951
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
    NCT03772587
    Condition:   Generalized Myasthenia Gravis
    Interventions:   Drug: M281;   Other: Placebo
    Sponsor:   Momenta Pharmaceuticals, Inc.
    Recruiting
  • Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
    NCT03759392
    Condition:   Heart Failure With Reduced Ejection Fraction
    Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
    Sponsors:   Amgen;   Cytokinetics;   Servier
    Recruiting
  • A Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
    NCT03759041
    Condition:   Ulcerative Colitis
    Interventions:   Drug: Vancomycin Pre-Treatment;   Drug: Placebo for Vancomycin Pre-Treatment;   Drug: SER-287;   Drug: Placebo for SER-287
    Sponsor:   Seres Therapeutics, Inc.
    Recruiting
  • A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
    NCT03713957
    Condition:   Parkinson Disease
    Interventions:   Drug: GRF6021;   Other: Placebo
    Sponsors:   Alkahest, Inc.;   Michael J. Fox Foundation for Parkinson's Research
    Recruiting
  • Study to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep
    NCT03679884
    Condition:   Insomnia Disorder
    Interventions:   Drug: ACT-541468 10 mg;   Drug: ACT-541468 25 mg;   Drug: ACT-541468 50 mg;   Drug: Placebo
    Sponsor:   Idorsia Pharmaceuticals Ltd.
    Recruiting
  • Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
    NCT03654313
    Conditions:   Atherosclerosis;   Cardiovascular Disease
    Interventions:   Biological: MEDI6570;   Biological: Placebo;   Biological: Part B Placebo
    Sponsor:   MedImmune LLC
    Recruiting
  • Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
    NCT03650114
    Condition:   Relapsing Multiple Sclerosis
    Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
    NCT03618095
    Condition:   Aortic Valve Stenosis
    Intervention:   Device: LOTUS Edge Valve System
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Safety and Efficacy of KPI-121 in Subjects With DED
    NCT03616899
    Condition:   Kerato Conjunctivitis Sicca
    Interventions:   Drug: KPI-121 Ophthalmic Suspension;   Drug: Vehicle
    Sponsor:   Kala Pharmaceuticals, Inc.
    Recruiting
  • Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
    NCT03587805
    Condition:   Atopic Dermatitis
    Intervention:   Drug: Tralokinumab
    Sponsor:   LEO Pharma
    Recruiting
  • ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
    NCT03587740
    Condition:   Breast Cancer
    Intervention:   Drug: T-DM1
    Sponsors:   Dana-Farber Cancer Institute;   Susan G. Komen Breast Cancer Foundation;   Gateway for Cancer Research
    Recruiting
  • PSD502 in Subjects With Premature Ejaculation
    NCT03578783
    Condition:   Premature Ejaculation
    Interventions:   Drug: Placebo;   Drug: PSD502
    Sponsor:   Plethora Solutions Ltd
    Recruiting
  • Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects Suffering From Difficulties to Sleep
    NCT03575104
    Condition:   Insomnia Disorder
    Interventions:   Drug: ACT-541468;   Other: Placebo
    Sponsor:   Idorsia Pharmaceuticals Ltd.
    Recruiting
  • A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
    NCT03573297
    Conditions:   Bipolar I Disorder;   Mania;   Depression
    Interventions:   Drug: Cariprazine;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
    NCT03544229
    Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis
    Interventions:   Drug: TAK-906 Maleate;   Drug: TAK-906 Maleate Placebo
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
    NCT03533114
    Condition:   Idiopathic Hypersomnia
    Interventions:   Drug: JZP-258;   Drug: Placebo Oral Solution
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  • Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
    NCT03521934
    Condition:   Heart Failure-Type 2 Diabetes Mellitus
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
    Sponsor:   Sanofi
    Recruiting
  • A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
    NCT03518034
    Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting
  • ECG Belt for CRT Response
    NCT03504020
    Condition:   Heart Failure
    Intervention:   Device: ECG Belt Research System
    Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
    Recruiting
  • Reducing Lung CongestIon Symptoms in Advanced Heart Failure
    NCT03499236
    Condition:   Heart Failure
    Interventions:   Device: V-Wave Interatrial Shunt;   Other: Control
    Sponsor:   V-Wave Ltd
    Recruiting
  • To Assess the Patients' Ability to Self-Administer Fasinumab
    NCT03491904
    Conditions:   Osteoarthritis, Knee;   Osteoarthritis, Hip
    Interventions:   Drug: Fasinumab AI;   Drug: Fasinumab PFS
    Sponsors:   Regeneron Pharmaceuticals;   Teva Pharmaceutical Industries, Ltd.
    Recruiting
  • FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study
    NCT03490201
    Condition:   Ventricular Tachycardia
    Interventions:   Device: Market Approved RF Ablation System;   Device: FlexAbility SE Ablation Catheter
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Benefits of µCor in Ambulatory Decompensated Heart Failure
    NCT03476187
    Condition:   Heart Failure
    Intervention:   Device: µCor
    Sponsor:   Zoll Medical Corporation
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies
    NCT03467152
    Condition:   Dementia With Lewy Bodies
    Interventions:   Drug: E2027;   Drug: Placebo
    Sponsor:   Eisai Inc.
    Recruiting
  • Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
    NCT03464136
    Condition:   Crohn Disease
    Interventions:   Biological: Placebo for Ustekinumab;   Biological: Placebo for Adalimumab;   Biological: Ustekinumab (6 mg/kg);   Biological: Ustekinumab (90 mg);   Biological: Adalimumab (40 mg)
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
    NCT03444870
    Condition:   Alzheimer Disease
    Interventions:   Drug: Gantenerumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
    NCT03443973
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Gantenerumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
    NCT03354598
    Condition:   Uncomplicated Urinary Tract Infections
    Interventions:   Drug: Sulopenem-Etzadroxil/Probenecid;   Drug: Ciprofloxacin
    Sponsor:   Iterum Therapeutics, International Limited
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
    NCT03345849
    Condition:   Crohn's Disease
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
    NCT03345836
    Condition:   Crohn's Disease
    Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
    NCT03334851
    Conditions:   Systemic Lupus Erythematosus;   Rheumatoid Arthritis
    Interventions:   Drug: PF-06835375;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus
    NCT03252587
    Condition:   Systemic Lupus Erythematosus
    Interventions:   Drug: BMS-986165;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Electronic Patient Reporting of Symptoms During Cancer Treatment
    NCT03249090
    Conditions:   Advanced Cancer;   Metastatic Cancer
    Interventions:   Other: Patient Self-Reporting of Symptoms;   Other: Usual Care Delivery
    Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   University of North Carolina;   Mayo Clinic;   American Society of Clinical Oncology;   American Cancer Society, Inc.;   Dana-Farber Cancer Institute
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
    NCT03175744
    Condition:   Critical Limb Ischemia
    Interventions:   Device: Stellarex DCB;   Device: PTA Catheter
    Sponsor:   Spectranetics Corporation
    Recruiting
  • An Effectiveness-Implementation Trial of SPIRIT in ESRD
    NCT03138564
    Condition:   End Stage Renal Disease
    Interventions:   Behavioral: SPIRIT;   Behavioral: Comparison Condition
    Sponsors:   Emory University;   National Institute of Nursing Research (NINR)
    Recruiting
  • Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization
    NCT03127722
    Condition:   Contraception
    Interventions:   Procedure: Blood draw;   Device: ESSURE (BAY1454032);   Procedure: Laparoscopic tubal sterilization
    Sponsor:   Bayer
    Recruiting
  • Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
    NCT03108456
    Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
    Interventions:   Device: Orbital Atherectomy;   Device: Balloon
    Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
    NCT03105102
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab SC;   Drug: risankizumab IV;   Drug: placebo for risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
    NCT03077412
    Condition:   Fistulizing Crohn's Disease
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
    Sponsors:   Gilead Sciences;   Galapagos NV
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
    NCT03071692
    Conditions:   Type2 Diabetes;   Dyslipidemia
    Interventions:   Drug: K-877;   Drug: Placebo
    Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
    Recruiting
  • Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
    NCT03061305
    Conditions:   Cancer;   Adult Solid Tumor;   Lymphoma
    Intervention:  
    Sponsor:   Strata Oncology
    Recruiting
  • Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
    NCT03046056
    Condition:   Small Bowel Crohn's Disease
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
    Sponsors:   Gilead Sciences;   Galapagos NV
    Recruiting
  • AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
    NCT03028740
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting
  • QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
    NCT03022825
    Condition:   Bladder Cancer
    Interventions:   Drug: ALT-803;   Drug: BCG
    Sponsor:   Altor BioScience
    Recruiting
  • Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
    NCT02926911
    Conditions:   DCIS;   Ductal Carcinoma in Situ
    Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
    Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
    Recruiting
  • Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
    NCT02914561
    Condition:   Crohn's Disease
    Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
    Sponsors:   Gilead Sciences;   Galapagos NV
    Recruiting
  • Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
    NCT02876835
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
    NCT02793583
    Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
    NCT02675114
    Condition:   Aortic Stenosis
    Interventions:   Procedure: Surgical aortic valve replacement (SAVR);   Device: Transcatheter Aortic Valve Replacement (TAVR)
    Sponsor:   Edwards Lifesciences
    Recruiting
  • Baroreflex Activation Therapy for Heart Failure
    NCT02627196
    Condition:   Heart Failure
    Interventions:   Device: BAROSTIM NEO® System;   Drug: Medical Management
    Sponsor:   CVRx, Inc.
    Recruiting
  • An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
    NCT02542696
    Condition:   Parkinson Disease
    Intervention:   Drug: APL-130277
    Sponsor:   Sunovion
    Recruiting
  • Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
    NCT02520778
    Conditions:   Advanced Lung Non-Squamous Non-Small Cell Carcinoma;   Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Drug: Navitoclax;   Drug: Osimertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02502266
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
    NCT02329327
    Condition:   Bleeding
    Intervention:   Biological: Andexanet
    Sponsors:   Portola Pharmaceuticals;   Population Health Research Institute
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
    NCT02138734
    Condition:   Non-muscle Invasive Bladder Cancer
    Interventions:   Biological: BCG+ALT-803;   Biological: BCG
    Sponsor:   Altor BioScience
    Recruiting
  • Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
    NCT02089217
    Condition:   Carotid Stenosis
    Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
    Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
    NCT02060630
    Condition:   Critical Limb Ischemia
    Interventions:   Procedure: Open surgical revascularization;   Device: Endovascular revascularization
    Sponsors:   New England Research Institutes;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Boston Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Dimethyl Fumarate (DMF) Observational Study
    NCT02047097
    Condition:   Multiple Sclerosis
    Intervention:   Drug: dimethyl fumarate
    Sponsor:   Biogen
    Recruiting
  • Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
    NCT01996865
    Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Celgene
    Recruiting
  • Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
    NCT01938248
    Conditions:   Atrial Fibrillation;   Stroke
    Interventions:   Drug: Apixaban;   Drug: aspirin
    Sponsors:   Population Health Research Institute;   Bristol-Myers Squibb;   Pfizer;   Medtronic;   Canadian Institutes of Health Research (CIHR);   Hamilton Health Sciences Foundation
    Recruiting
  • Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
    NCT01729455
    Condition:   Systemic Lupus Erythematosus
    Interventions:   Biological: BENLYSTA;   Other: SLE treatment
    Sponsors:   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Psoriasis Longitudinal Assessment and Registry (PSOLAR)
    NCT00508547
    Conditions:   Psoriasis;   Arthritis, Psoriatic
    Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity
    NCT03746522
    Conditions:   Bardet Biedl Syndrome (BBS);   Alström Syndrome (AS)
    Interventions:   Drug: Setmelanotide;   Drug: Placebos
    Sponsor:   Rhythm Pharmaceuticals, Inc.
    Recruiting
  • Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
    NCT04029116
    Condition:   Recurrent Vulvovaginal Candidiasis
    Interventions:   Drug: Fluconazole Tablet;   Drug: IBREXAFUNGERP;   Drug: Placebo oral tablet
    Sponsor:   Scynexis, Inc.
    Recruiting
  • Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis
    NCT04146363
    Condition:   Atopic Dermatitis
    Interventions:   Biological: Lebrikizumab;   Other: Placebo
    Sponsor:   Dermira, Inc.
    Recruiting
  • Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
    NCT04052425
    Condition:   Non-segmental Vitiligo
    Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle
    Sponsor:   Incyte Corporation
    Recruiting
  • A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
    NCT03539601
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Crisaborole ointment, 2%;   Drug: Hydrocortisone butyrate cream, 0.1%;   Drug: Pimecrolimus cream, 1%;   Drug: Crisaborole Vehicle
    Sponsor:   Pfizer
    Recruiting
  • Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
    NCT03893448
    Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
    Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
    NCT03627767
    Conditions:   Dermatitis;   Dermatitis, Atopic;   Eczema;   Skin Diseases;   Skin Diseases, Genetic;   Genetic Diseases, Inborn;   Skin Diseases, Eczematous;   Hypersensitivity;   Hypersensitivity, Immediate;   Immune System Diseases
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Disrupt CAD III With the Shockwave Coronary IVL System
    NCT03595176
    Conditions:   Coronary Artery Disease;   Myocardial Infarction
    Intervention:   Device: Lithotripsy
    Sponsor:   Shockwave Medical, Inc.
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
    NCT03105128
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
    NCT03104413
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
    Sponsor:   AbbVie
    Recruiting
  • Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
    NCT03013543
    Conditions:   Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic);   Leptin Receptor Deficiency Obesity;   Bardet-Biedl Syndrome;   Alstrom Syndrome;   Smith-Magenis Syndrome
    Intervention:   Drug: Setmelanotide
    Sponsor:   Rhythm Pharmaceuticals, Inc.
    Recruiting
  • Chronic Hypertension and Pregnancy (CHAP) Project
    NCT02299414
    Condition:   Hypertension
    Interventions:   Drug: Anti-hypertensive therapy;   Other: No anti-hypertensive therapy (unless BP is severe)
    Sponsors:   University of Alabama at Birmingham;   Columbia University;   Drexel University College of Medicine;   Rutgers, The State University of New Jersey;   Lehigh Valley Hospital;   Saint Peters University Hospital;   Christiana Care Health Services;   Washington University School of Medicine;   Duke University;   University of Texas Southwestern Medical Center;   The University of Texas Health Science Center, Houston;   Stanford University;   University of Pennsylvania;   The University of Texas Medical Branch, Galveston;   University of Utah;   Intermountain Health Care, Inc.;   University of California, San Francisco;   Johns Hopkins University;   University of Pittsburgh;   Ochsner Health System;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI);   WakeMed Health and Hospitals;   San Francisco General Hospital;   McKay-Dee Hospital;   Winthrop University Hospital;   New York Hospital Queens;   Latter Day Saints Hospital;   Lyndon B Johnson General Hospital;   Virtua Medical Group;   Bayview Medical Center;   Duke Regional Hospital;   Utah Valley Regional Medical Center;   Northwestern;   Brown (WIHRI);   Baylor College of Medicine;   Case Western/Metro Health;   Ohio State University;   University of Iowa;   University of California, San Diego;   Indiana University;   Unity Point Health-Meriter Hospital WI;   Weill Medical College of Cornell University;   University of Oklahoma;   Medical University of South Carolina;   Beaumont Hospital;   University of Colorado, Denver;   University of Kansas Medical Center;   Denver Health and Hospital Authority;   Gundersen Health System;   Aurora Health Care;   Oregon Health and Science University;   Medical College of Wisconsin;   Temple University;   New Jersey Medical School;   University of South Alabama;   Vanderbilt University;   University of Arkansas;   Miami Valley Hospital;   Emory University;   St. Luke's Hospital and Health Network, Pennsylvania;   Cleveland Clinic Fairview Hospital;   University of Tennessee Health Science Center;   TriHealth Inc.;   Cleveland Clinic Hillcrest Hospital;   Tulane University;   Yale University;   Arrowhead Regional Medical Center;   Geisinger Clinic
    Recruiting
  • Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
    NCT02202434
    Condition:   Aortic Stenosis
    Interventions:   Device: Lotus Valve System;   Device: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System;   Device: LOTUS Edge Valve System
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting
  • Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
    NCT01442194
    Condition:   Multiple Sclerosis
    Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
    NCT00271180
    Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
    Intervention:   Device: Device
    Sponsor:   Medtronic
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC